Do you identify as LGBTQ+ or queer, and have you gone through all or part of a family planning process? Or, do you aid LGBTQ+ individuals in their family planning as part of your work? If so, we are seeking perspectives on these processes and the types of stress and social support experienced during them.

Efgartigimod has been approved by the U.S. FDA (Food and Drug Administration) as a treatment for adult patients with gMG in whom AChR-Ab's are present. However, it was not approved it for the form of gMG that is AChR Ab seronegative (antibodies not present). and therefore this study is now testing how efragtigimod works in patients without any antibodies,

Do you have Hidradenitis Suppurativa (HS)? You may be eligible to participate in a research study assessing the effect of an investigational product in HS and its impact on quality of life. If eligible, and you decide to participate, you will receive the study drug study related medical evaluation and compensation for completed visits.

Have you been diagnosed with Blood Cancer. If so, you may be able to take part in a research study looking at the safety of giving a new drug called AK117 to patients with Leukemia

Would you like to learn more about how our thinking changes as we get older? If you're between 65-85 years old, you could join a study to find out how aging affects how well we can guess words. Compensation provided.

Have you been diagnosed with s Cutaneous (skin) Lymphoma? If so this could be a good study for you to paticipate in. One of the primary goals of the USCLC is to establish a registry of patients with cutaneous lymphoma in the United States. Such a registry would collect information such as the specific cutaneous lymphoma diagnosis, stage of disease, treatments used, and response to treatments. This information will collected on an online Institutional Review Board (IRB)-approved database/registry of patients from all sites. We hope that this will allow providers to better understand this rare disease by looking at data from many patients. We hope ultimately will include all the patients with cutaneous lymphoma across the United States

Have you been histologically or cytologically confirmed to have Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies? If so, you may be able to participate in a research study seeking to find out if Amivantamab Monotherapy and/or Amivantamab in Addition to Standard of Care Therapeutic Agents can be an effective traetment.

The study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage.

Have you been diagnosed with Chronic Myeloid Leukemia, have a T315I mutation, and previously treated with at least two tyrosine kinase inhibitors (TKIs)? You might be able to participate in this study.

Are you a male that has been diagnosed with hormone receptor positive and HER2 negative breast cancer? If so, you may be eligible to a clinical trial comparing different endocrine therapies to treat breast cancer prior to surgery.